Central Nervous System Fungal Infections
MYCOSES of the brain, spinal cord, and meninges which may result in ENCEPHALITIS; MENINGITIS, FUNGAL; MYELITIS; BRAIN ABSCESS; and EPIDURAL ABSCESS. Certain types of fungi may produce disease in immunologically normal hosts, while others are classified as opportunistic pathogens, causing illness primarily in immunocompromised individuals (e.g., ACQUIRED IMMUNODEFICIENCY SYNDROME).
Microascus cinereus (Anamorph scopulariopsis) brain abscess in a bone marrow transplant recipient. (1/73)
We report the first documented case of brain abscess due to the dematiaceous fungus Microascus cinereus, an organism common in soil and stored grain. M. cinereus was isolated from brain abscess material from a bone marrow transplant recipient. The patient responded well to treatment by amphotericin B lipid complex, itraconazole, and a craniotomy but later died from secondary complications caused by graft-versus-host disease. (+info)SCH 56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum ("Ramichloridium mackenziei"). (2/73)
Ramichloridium obovoideum ("Ramichloridium makenziei") is a rare cause of lethal cerebral phaeohyphomycosis. It has been, so far, geographically restricted to the Middle East. BALB/c mice were inoculated with two strains of R. obovoideum intracranially. Therapy with amphotericin B, itraconazole, or the investigational triazole SCH 56592 was conducted for 10 days. Half the mice were monitored for survival and half were killed for determination of the fungal load in brain tissue. Recipients of SCH 56592 had significantly prolonged survival and lower brain fungal burden, and this result was found for mice infected with both of the fungal strains tested. Itraconazole reduced the brain fungal load in mice infected with one strain but not the other, while amphotericin B had no effect on brain fungal concentrations. This study indicates a possible role of SCH 56592 in the treatment of the serious cerebral phaeohyphomycosis due to R. obovoideum. (+info)Recurrent blastomycosis of the central nervous system: case report and review. (3/73)
Although blastomycosis of the central nervous system (CNS) occurs in approximately 4% of patients with blastomycosis, recurrent CNS blastomycosis is very rare. We review the clinical features, treatment, and outcome of 4 previously reported cases. We also report a case of recurrent CNS blastomycosis successfully treated with surgery and liposomal amphotericin B after an inadequate response to amphotericin B therapy. This treatment may be an alternate approach for management of similar cases. (+info)Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. (4/73)
The central nervous system (CNS) distribution and antifungal efficacy of all 4 approved formulations of amphotericin B (AmB) were investigated in a rabbit model of hematogenous Candida albicans meningoencephalitis. Treatment with AmB deoxycholate (1 mg/kg/day) or liposomal AmB (5 mg/kg/day) yielded the highest peak plasma concentration (C(max)), area under concentration versus time curve from zero to 24 h (AUC(0-24)), and time during dosing level tau Ttau>minimum inhibitory complex (MIC) values and led to complete eradication of C. albicans from brain tissue (P<.05 vs. untreated controls). By comparison, AmB colloidal dispersion and AmB lipid complex (5 mg/kg/day each) were only partially effective (not significant vs. untreated controls). There was a strong correlation of C(max), AUC(0-24), C(max)/MIC, AUC(0-24)/MIC, and Ttau>MIC with clearance of C. albicans from brain tissue (P+info)Molecular variability of Pseudallescheria boydii, a neurotropic opportunist. (5/73)
The sequences of the internal transcribed spacer (ITS) ribosomal DNA (rDNA) domain data obtained by restriction fragment length polymorphism analysis with 18S rDNA and fingerprinting (M13) for clinical and environmental strains of Pseudallescheria boydii (anamorph, Scedosporium apiospermum) were compared to those for related species of Pseudallescheria, Petriella, and Scedosporium. The infraspecific variability of P. boydii was considerable. There were five different lengths in the 18S rDNAs within P. boydii due to the occurrence of introns. In several cases, strains isolated from a single pond or ditch proved to be genetically very different. Nevertheless, some lineages had a regional distribution. The variability found is unlikely to be explained by meiotic recombination alone. Pseudallescheria fusoidea, Pseudallescheria ellipsoidea, and Pseudallescheria angusta were found to be synonyms for P. boydii. Scedosporium prolificans was found amid Petriella species in the ITS tree and showed no infraspecific variability. The type strain of Rhinocladium lesnei proved to be identical to Graphium putredinis. Acladium castellanii, which is morphologically reminiscent of S. apiospermum, was also found to be a separate species, but with an unknown affiliation. (+info)Aspergillosis case-fatality rate: systematic review of the literature. (6/73)
To update the case-fatality rate (CFR) associated with invasive aspergillosis according to underlying conditions, site of infection, and antifungal therapy, data were systematically reviewed and pooled from clinical trials, cohort or case-control studies, and case series of >/=10 patients with definite or probable aspergillosis. Subjects were 1941 patients described in studies published after 1995 that provided sufficient outcome data; cases included were identified by MEDLINE and EMBASE searches. The main outcome measure was the CFR. Fifty of 222 studies met the inclusion criteria. The overall CFR was 58%, and the CFR was highest for bone marrow transplant recipients (86.7%) and for patients with central nervous system or disseminated aspergillosis (88.1%). Amphotericin B deoxycholate and lipid formulations of amphotericin B failed to prevent death in one-half to two-thirds of patients. Mortality is high despite improvements in diagnosis and despite the advent of newer formulations of amphotericin B. Underlying patient conditions and the site of infection remain important prognostic factors. (+info)Isolation of a Nodulisporium species from a case of cerebral phaeohyphomycosis. (7/73)
A fungal infection of the brain of a 55-year-old male patient is reported. The lesion and involved fungus were located exclusively in the right medial temporo-parietal region. The patient was successfully treated with surgical resection of the lesion and antifungal chemotherapy. Few pathogenic dematiaceous fungi exhibit neurotropism and can cause primary infection in the central nervous system (CNS). The etiological agent is described as a Nodulisporium species. To date Nodulisporium has never been reported as an agent of CNS infection in humans. (+info)Antifungal therapy for central nervous system histoplasmosis, using a newly developed intracranial model of infection. (8/73)
The outcome of central nervous system (CNS) histoplasmosis is often unfavorable. Although fluconazole plays an integral role in treatment of fungal meningitis, its role in the treatment of histoplasmosis is hampered by reduced activity and potential development of resistance. A murine model of CNS histoplasmosis was used to evaluate the hypothesis that a combination of amphotericin B and fluconazole therapy would be superior to amphotericin B monotherapy. Groups of B6C3F(1) mice were infected by injection of Histoplasma capsulatum into the subarachnoid space. The addition of fluconazole hindered the antifungal effect of amphotericin B, as determined by measurement of fungal burden, suggesting antagonism in the brain. Fluconazole was less effective as a single agent than was amphotericin B, despite the greater penetration of fluconazole into brain tissues. The hypothesis that amphotericin B-fluconazole combination therapy would be superior to amphotericin B monotherapy for treatment of CNS histoplasmosis was not supported by this study. (+info)Central nervous system fungal infections are invasive mycoses caused by pathogenic fungi that penetrate the blood-brain barrier, leading to inflammation and damage of brain parenchyma, often resulting in severe neurological deficits or even death if not promptly diagnosed and treated.
Central nervous system (CNS) fungal infections refer to invasive fungal diseases that affect the brain and/or spinal cord. These types of infections are relatively uncommon but can be serious and potentially life-threatening, especially in individuals with weakened immune systems due to conditions such as HIV/AIDS, cancer, or organ transplantation.
There are several types of fungi that can cause CNS infections, including:
1. Candida species: These are yeast-like fungi that can cause a range of infections, from superficial to systemic. When they invade the CNS, they can cause meningitis or brain abscesses.
2. Aspergillus species: These are mold-like fungi that can cause invasive aspergillosis, which can affect various organs, including the brain.
3. Cryptococcus neoformans: This is a yeast-like fungus that primarily affects people with weakened immune systems. It can cause meningitis or brain abscesses.
4. Coccidioides species: These are mold-like fungi that can cause coccidioidomycosis, also known as Valley Fever. While most infections are limited to the lungs, some people may develop disseminated disease, which can affect the CNS.
5. Histoplasma capsulatum: This is a mold-like fungus that causes histoplasmosis, which primarily affects the lungs but can disseminate and involve the CNS.
Symptoms of CNS fungal infections may include headache, fever, altered mental status, seizures, stiff neck, and focal neurologic deficits. Diagnosis typically involves a combination of clinical evaluation, imaging studies (such as MRI or CT), and laboratory tests (such as cerebrospinal fluid analysis or fungal cultures). Treatment usually involves long-term antifungal therapy, often with a combination of drugs, and may also include surgical intervention in some cases.